newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical trial of SEL-302